Rheumatologists lined up to tout olokizumab in RA

7 June 2021

Russian pharma company R-Pharm has highlighted the views of four leading rheumatologists on its rheumatoid arthritis (RA) drug candidate olokizumab, which successfully completed international Phase III trials in 2020.

They discussed the direct targeting of interleukin (IL)-6 ligand with a focus on olokizumab during a satellite symposium held by R-Pharm at the annual European Congress of Rheumatology (EULAR 2021) event.

"Being highly effective in the overall TNF-IR populations, olokizumab emerges as a new and promising therapy"Ernest Choy, Cardiff University School of Medicine, UK, spoke of the advantages of IL-6 ligand against receptor inhibition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK